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SUMMARY
Mitochondrial apoptosis can be effectively targeted in lymphoid malignancies with the FDA-
approved B-cell lymphoma 2 (BCL-2) inhibitor venetoclax, but resistance to this agent is 
emerging. We show that venetoclax resistance in chronic lymphocytic leukemia is associated with 
complex clonal shifts. To identify determinants of resistance, we conducted parallel genome-scale 
screens of the BCL-2-driven OCI-Ly1 lymphoma cell line after venetoclax exposure along with 
integrated expression profiling and functional characterization of drug-resistant and engineered 
cell lines. We identified regulators of lymphoid transcription and cellular energy metabolism as 
drivers of venetoclax resistance in addition to the known involvement by BCL-2 family members, 
which were confirmed in patient samples. Our data support the implementation of combinatorial 
therapy with metabolic modulators to address venetoclax resistance.
Graphical Abstract
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Mitochondrial apoptosis is governed by the B-cell lymphoma 2 (BCL-2) family including 
both pro- and anti-apoptotic proteins. Across cancers, apoptosis dysregulation can result 
from overexpression of the anti-apoptotic BCL-2 protein that can sequester certain pro-
apoptotic BH3-only proteins (BIM, BID) to avoid oligomerization of pore-forming proteins 
(BAX, BAK) and subsequent mitochondrial outer membrane permeabilization. Within B-
cell tumors, BCL-2 dysregulation commonly arises from genetic abnormalities. These 
include the translocation t(14;18)(q32;q21), which places BCL2 under the control of IGH 
promoter, in follicular lymphoma (Tsujimoto et al., 1985; Kridel et al., 2012) or focal 
deletion of chromosome 13 (del[13q14]), which leads to loss of miR-15a/16-1, a negative 
regulatory microRNA of BCL-2, in chronic lymphocytic leukemia (CLL) (Cimmino et al., 
2005). Thus, BCL-2 has been a rational therapeutic target in lymphoid cancers.
Venetoclax is an FDA-approved BCL-2 inhibitor for the treatment of CLL (Roberts et al., 
2016) and for acute myeloid leukemia (AML) (DiNardo et al., 2018). It displaces pro-
apoptotic BH3-only proteins from BCL-2, allowing them to activate the pro-apoptotic BAX 
or BAK proteins (Del Gaizo Moore et al., 2008). Despite its potent clinical activity in even 
those CLL cases failing control with chemotherapy regimens such as those carrying 
disruption of TP53 (Roberts et al., 2016), disease progression on venetoclax is an emerging 
therapeutic challenge (Anderson et al., 2017; Mato et al., 2018). Here, we aimed to uncover 
the determinants of venetoclax resistance in lymphoid malignancies.
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Resistance to venetoclax in patients is associated with complex patterns of clonal 
evolution
Gene mutations are well-known mechanisms of resistance to targeted therapy in CLL 
(Woyach et al., 2014). To determine whether consistent genetic alterations could be observed 
in CLL patients demonstrating venetoclax resistance, we performed matched whole-exome 
sequencing (WES) of DNA from leukemia samples collected from 6 patients before 
venetoclax treatment and at the time of relapse compared to germline DNA (Figure 1A, 
Tables S1, S2 and S3). All patients had been previously treated with chemoimmunotherapy. 
After starting venetoclax, all experienced partial response and progressed after a median of 
12.3 months (range, 5.1-22.8 months) on therapy. Progression was assessed in blood for 3 
patients, in marrow for 2 patients and in lymph node for 1 patient.
Analysis of the WES data revealed no differences in the median mutation rate between 
baseline and relapse samples across patients (Figure S1A). We did not identify any somatic 
single-nucleotide variations (sSNVs) in BCL2 itself at baseline or at progression, nor in any 
coding region of BCL-2 family members (Table S4). Inference of subclonal architecture 
revealed marked clonal shifts in all patients (Figure 1B, Figure S1B-S1C, Table S4). 
Numerous instances of shifting cancer cell fractions of subclones with CLL drivers such as 
ATM, TP53 or SF3B1 mutation were observed, even of distinct subclones with differing 
mutated alleles of the same gene within an individual (Figure 1C), but no sSNVs of known 
CLL driver mutations were consistently selected with resistance.
We noted that Patients 1 and 2 share a common evolutionary trajectory where resistance was 
associated with a large expansion of a subclone carrying del(17p) [TP53], amp(8q) and 
del(8p) [encompasses the TRAIL receptor genes] together with truncal SF3B1 and TP53 
mutations (Figure 1B-1C, Figure S1C). We previously described enrichment of del(8p) in 
the setting of resistance to the BTK inhibitor ibrutinib (Burger et al., 2016), and BCL-2 
inhibition has been shown to sensitize human cancer cells to TRAIL-induced apoptosis by 
inducing the expression of its receptor (Song et al., 2008). Our finding of amp(8q) (MYC 
locus) together with the recently reported del(9p) (CDKN2A/B locus) in leukemia samples 
from venetoclax resistant CLL patients (Herling et al., 2018) supports the idea that changes 
in cell cycle regulation contribute to resistance. Altogether, these results suggested that 
venetoclax resistance is not solely driven by any particular sSNV or somatic copy number 
variation (sCNV) but rather involves multiple complex changes. Such observations prompted 
us to undertake an unbiased genome-wide screening approach to uncover drivers of 
venetoclax resistance.
BCL-2 family members, lymphoid transcription regulators and components of AMP-
dependent pathways are candidate drivers of venetoclax resistance
We performed parallel genome-scale loss-of-function (LOF) and gain-of-function (GOF) 
genetic modifier screens, using the BCL-2-driven OCI-Ly1 lymphoma cell line (Figure 2A). 
This cell line was selected for its sensitivity to venetoclax and ability to be transduced, 
amongst the 6 lymphoid lines evaluated (Figure S2A). For the LOF screen, OCI-Ly1 cells 
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modified to stably express Cas9 were infected with the Brunello lentiviral library of 76,441 
sgRNAs targeting 19,114 genes and 1,000 control sgRNAs (Doench et al., 2016), and treated 
with venetoclax (or DMSO, as control) for 14 days (Figure S2B). We then evaluated changes 
in sgRNA representation following drug treatment by targeted sequencing of genomic DNA 
isolated from viable cells on day 14. Although average sgRNA representation was overall 
decreased in the transduced cells treated with venetoclax compared to duplicate sets of 
untreated and DMSO-treated transduced cells, a clear subset of drug-treated transduced cells 
was enriched (Figure 2B). By analysis with the STARS software (v1.3, Broad Institute) 
(Doench et al., 2016), sgRNAs corresponding to 11 genes were consistently enriched over 2 
replicates after 14 days of drug treatment compared to DMSO (STARS score > 4; Figure 2C, 
Table S5), with high consistency in the changes in representation amongst the 4 sgRNAs per 
gene (Figure S2C). Not surprisingly, four of 11 knocked-out genes encoded pro-apoptotic 
BCL-2-family proteins (PMAIP1, BAX, BAK1, BCL2L11). Moreover, the level of 
representation by sgRNAs corresponding to the other BCL-2 members matched their known 
functions as either pro- or anti-apoptotic family members (Figure S2D). Notably, the other 7 
candidate hit genes were not BCL-2-family genes but were involved in pathways highly 
relevant to lymphoid biology. These included NFKBIA, encoding an inhibitor of the NF-κB 
pathway, and genes encoding lymphoid transcription factors and modulators (IKZF5, ID3, 
EP300, NFIA) or components of the processes of ubiquitination (OTUD5, UBR5). Several 
of the discovered genes are recurrently mutated in B-cell malignancies: EP300 in 10-20% of 
follicular lymphomas (Morin et al., 2011; Pastore et al., 2015), ID3 in 68% of Burkitt 
lymphomas (Love et al., 2012), NFKBIA in 20% of Hodgkin lymphomas (Weniger and 
Küppers, 2016), and UBR5 in 18% of mantle cell lymphomas (Meissner et al., 2013).
In an analogous fashion, we performed a GOF screen by using a genome-scale library 
including 17,255 barcoded ORFs encoding 12,952 unique proteins with at least 99% 
nucleotide and protein match to comprehensively identify genes that confer resistance to 
venetoclax when overexpressed in OCI-Ly1 cells (Figure 2A, Figure S2B). A clear shift of 
ORF representation was observed (Figure 2D,) and a total of 71 ORFs (arising from 70 
genes) had a log2fold change (LFC) greater than 2 (Figure 2E, Table S6). The top four genes 
that generated resistance when overexpressed were those encoding known anti-apoptotic 
proteins (BCL2L1, BCL2L2, BCL2, MCL1). Included among the top 50 genes identified in 
the screen were those encoding components of the energy-stress sensor PKA/AMPK 
signaling pathway (ADIPOQ, PRKAR2B, PRKAA2), of mitochondrial energy metabolism 
(SLC25A3) or vesicle transport/autophagy (RNF26, DNM2, PRKD2, ATG5), ribosomal 
proteins (RPL17, RPS4Y1, RPS15A), or components of ubiquitination (OTUD6A, FBXO9, 
USP54) (Figure 2E).
To confirm the LOF screen results, we generated single-gene knockout OCI-Ly1 cell lines 
for each of the 11 hits (2 cell lines per gene, generated from the 2 most efficient sgRNAs per 
gene). We also generated control lines corresponding to 2 non-targeting sgRNAs and for 2 
sgRNAs targeting TP53 (Figure S2E). From the GOF screen, we detected genes encoding 
two protein kinases components from related signaling pathways (PRKAR2B, PRKAA2). 
We hence prioritized the generation of 2 overexpression lines from OCI-Ly1 cells, one with 
the regulatory subunit of cAMP-dependent protein kinase (protein kinase A, PKA) encoded 
by PRKAR2B and the other the catalytic subunit of the AMP-activated protein kinase 
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(AMPK) encoded by PRKAA2 (Figure S2F). Both are key regulators of cellular energy 
metabolism (Lark et al., 2015; Lin and Hardie, 2018).
Across the individual knockout cell lines, we observed diminished sensitivity to venetoclax, 
with median increase in IC50 of 2.1-fold (range, 1.3- to 13.8-fold; p < 0.05, extra-sum-of-
squares F test) compared to the two cell lines transduced with non-targeting control sgRNAs 
(Figure 2F, Figure S2G). Moreover, all of the knockout and overexpression lines showed 
increased cumulative growth over 10 days of in vitro venetoclax exposure compared to 
control lines (Figure 2G), which was not observed in the absence of venetoclax (Figure 
S2H). Exposure of the knockout cell lines to venetoclax increased the degree of depletion of 
the targeted protein and enriched the frequency of frameshift indels generated by the 
introduction of sgRNAs into the cell lines (Figure S2E and S2I). Altogether, these results 
confirmed the on-target effects of the sgRNAs and the ORFs identified through the parallel 
genome-wide screens.
Venetoclax resistance involves MCL-1 overexpression and changes in cellular energy 
metabolism
In complementary experiments, we characterized the transcript and protein expression 
profiles of a venetoclax-resistant cell line (OCI-Ly1-R, IC50 1 μM), generated through 
chronic in vitro drug exposure of the parental (OCI-Ly1-S, IC50 4 nM) cells (Figure 3A). By 
RNA-sequencing (RNA-Seq) of the resistant and sensitive cell lines, we identified 19 
upregulated and 28 downregulated genes (adjusted p value < 0.05; ∣LFC∣ > 2) (Figure S3A). 
Comparison of the transcriptomes and the proteomes (identified via mass spectrometry-
based proteomics) of the OCI-Ly1-S and OCI-Ly1-R cells revealed close concordance 
across these two platforms (R2 = 0.4, all genes; R2 = 0.8, restricted to differentially 
expressed genes; Figure 3B), with 14 upregulated and 13 downregulated proteins (adjusted p 
value < 0.05, ∣LFC∣ > 2). MCL-1 emerged as the only significantly and coordinately 
deregulated transcript and protein that also overlapped with the gene hits from the genome-
scale screens (Figure 3B). MCL-1 overexpression has been previously reported in the 
characterizations of cancer cell lines rendered resistant to BCL-2 inhibition and has been 
described to sequester the pro-apoptotic BIM protein (Deng et al., 2007; Yecies et al., 2010). 
We confirmed the relative increase in protein expression of MCL-1 in OCI-Ly1-R cells 
compared to OCI-Ly1-S cells (Figure 3C), and observed in vitro synergy between 
venetoclax and the MCL-1 inhibitor S63845 (Kotschy et al., 2016) on OCI-Ly1-S cells 
(combination index <1, Figure 3D-3E). MCL-1 inhibition furthermore restored venetoclax 
sensitivity to the OCI-Ly1-R cells (Figure 3F). These results confirm a key role of MCL-1 
overexpression in mediating venetoclax resistance.
Geneset enrichment analysis (GSEA) based on RNA-Seq data revealed 35 significantly 
enriched pathways (nominal p value < 0.05, FDR < 0.25). Consistent with the results from 
our survival screens, top positively regulated pathways included lymphoid differentiation 
and chromatin maintenance, while top negatively regulated pathways related to metabolism 
and the endoplasmic reticulum (nominal p value < 0.002, FDR < 0.9) (Figure 4A, Table S7). 
In addition, the most coordinately upregulated transcripts and proteins originated from genes 
critical to cellular metabolism (AOX1, GLUL, PAPSS1, GATM, TSTD1, GALM, FBP1) 
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(Figure 3B). Glutamine synthetase (encoded by GLUL) plays a key role in cell survival 
(Bott et al., 2015), while repression of fructose-bisphosphatase 1 (encoded by FBP1) was 
previously shown to efficiently promote glycolysis (Guo et al., 2018). Other mechanisms of 
potential interest, highlighted by other upregulated transcripts/proteins, included cell cycle 
regulation (CDK6, CDKN1A [encoding p21], TT39C), B-cell biology (DOCK10) as well as 
autophagy or mitophagy, a process for removing damaged mitochondria through autophagy 
(DENND3, OPTN) and reactive oxygen species generation (CYBB).
Metabolic reprogramming plays a critical role in the resistance to BCL-2 inhibition
Given the dysregulation of proteins critical to AMPK signaling and energy metabolism in 
both the GOF screen and in OCI-Ly1-R cells, we hypothesized that metabolic 
reprogramming contributes to resistance of malignant B cells to venetoclax. A recent 
genome-wide CRISPR screen identified AMPK subunits as positive regulators of oxidative 
phosphorylation (OXPHOS) (Arroyo et al., 2016). We therefore evaluated mitochondrial 
respiration of the OCI-Ly1-R cells compared to OCI-Ly1-S cells, as well as of venetoclax-
resistant SU-DHL4 lymphoma cells (IC50 2.2 μM), which we generated through chronic in 
vitro drug exposure of the parental cell line (IC50 301 nM) (Figure S3B). For both sets of 
cell lines, we measured the oxygen consumption rate at baseline and over time in response to 
modulators of the mitochondrial electron transport chain (ETC) and OXPHOS. Both 
resistant cell lines demonstrated markedly higher rates of basal and maximal oxygen 
consumption, nearly all of which was coupled to ATP production by OXPHOS. Uncoupled 
rates of respiration were also markedly higher, suggesting an overall increased capacity for 
respiration and OXPHOS (Figure 4B, p < 0.0001). Resistant lines also demonstrated higher 
steady state levels of reactive oxygen species and higher mitochondrial membrane potential 
than parental lines (Figure 4C, Figure S3C). This was a result in part of an increased mass of 
mitochondria per cell in the resistant cells, since the quantity of mitochondrial DNA 
(mtDNA) was greater in the drug-resistant than –sensitive cells (Figure 4D).
To investigate whether venetoclax directly affects cellular energy metabolism, we measured 
oxygen consumption of both sets of OCI-Ly1 and SU-DHL4 resistant and parental cell lines 
following acute venetoclax exposure. Consistent with impairment of OXPHOS by 
venetoclax, we observed an immediate decrease in oxygen consumption (by 2-fold within 20 
minutes after drug exposure for OCI-Ly1) (Figure 4E, p < 0.0001). OCI-Ly1-R exhibited a 
higher basal level of glycolysis, as assessed by extracellular acidification rate (ECAR) 
(Figure 4F, p < 0.0001), and we observed an immediate, yet transitory, increase in ECAR 
following venetoclax in the sensitive but not in the resistant cells (Figure 4F). In these 
experiments, the impact of venetoclax on OXPHOS was independent of caspase activation-
related apoptotic cell death, as it was not fully prevented with the caspase inhibitor zVAD. 
The impact of venetoclax was however dependent on mitochondrial outer membrane 
permeabilization since exposure of the BAX/BAK1 double knockout OCI-Ly1 cell line to 
venetolcax did not result in demonstrable decrease in OXPHOS (Figure 4G, Figure S3D).
To investigate whether targeting AMPK and OXPHOS can impact venetoclax resistance, we 
treated multiple cell lines with venetoclax along with inhibitors and activators targeting the 
implicated pathways. The AMPK inhibitor dorsomorphin (compound C), the inhibitors of 
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the ETC complex III (antimycin A) and complex V (oligomycin) increased venetoclax 
sensitivity when applied to the OCI-Ly1, SU-DHL4, SU-DHL6 lymphoma cell lines and the 
Toledo AML cell line (Figure 5A, Figure 5B, Figure S4A). These 3 compounds also 
increased the sensitivity to venetoclax in 10 of 10 primary CLL samples tested (Figure 5C, 
Figure S4B, Table S1). Conversely, treatment of cell lines with the AMPK activator 
A-769662 lowered sensitivity to venetoclax (Figure 5D). Furthermore, dorsomorphin, 
oligomycin and antimycin A could restore sensitivity to venetoclax in both the OCI-Ly1-R 
and SU-DHL4-R cells (Figure 5E). In vivo, we noted a higher efficacy of the oligomycin A 
and venetoclax combination compared to either drug alone when administered to OCI-Ly1 
xenografts in NSG mice (Figure 5F). Altogether, these results implicate AMPK activation 
and mitochondrial metabolic reprogramming in resistance to venetoclax both in vitro and in 
vivo.
Venetoclax resistance involves a resistance circuit of ID3, AMPK, and PKA
To define possible mechanisms by which the candidate hit genes identified from the survival 
screens were related to venetoclax resistance, we first evaluated MCL-1 expression in the 
respective knockout and overexpression cell lines. None of 14 tested cell lines demonstrated 
elevated MCL-1 levels before or after 14 days of treatment with venetoclax (Figure S5A-
S5B) nor clear sensitivity to MCL-1 inhibition (Figure S5C), suggesting their engagement in 
alternative resistance mechanisms. Transcriptome profiling of each of the knockout cell lines 
corresponding to the 6 non-BCL-2 family member gene candidates revealed the greatest 
similarity between the knockout line of the lymphoid transcription regulator ID3 and the 
OCI-Ly1-R line (Figure 6A). Shared were transcripts involved in lymphoid signaling 
(PLCL2, KCNA3, PAG1) or transcription (XBP1), metabolism (CYP2U1, CYBB), 
apoptosis (TNFRSF21) and Ras signaling (DIRAS1, GNG7, RAPGEF5). Of note, ID2 (an 
ID3 paralog) was amongst the coordinately deregulated transcripts and proteins in the OCI-
Ly1-R cell line (indicated in Figure 3B). As for the OCI-Ly1 cells, we confirmed that 
knockout of ID3 led to a survival advantage in SU-DHL4 cells exposed to venetoclax as well 
(Figure S5D-S5E-S5F).
The most significantly upregulated gene in the ID3 knockout cells in OCI-Ly1 cells was 
PRKAR2B, a PKA subunit which we previously uncovered in the GOF screen; we further 
confirmed its overexpression in ID3 KO SU-DHL4 cells (Figure 6B, Figure S5G). To clarify 
how the dominant-negative transcription factor ID3 regulates PRKAR2B expression, we 
performed ATAC-seq of the ID3 knockout (vs control) OCI-Ly1 lines in order to determine 
differential signatures of chromatin accessibility and transcription factor engagement. 
Notably, we identified increased accessibility associated with TCF3 motifs genome-wide in 
the ID3 knockout cells. TCF3 is a lymphoid transcription regulator previously reported to 
interact with ID3 (Figure 6C) (Wang and Baker, 2015), as well as to be involved in the 
transcription of ADIPOQ, which was detected in the GOF screen (Doran et al., 2008). A 
similar increase in TCF3 motif accessibility was also observed when comparing OCI-Ly1-R 
vs OCI-Ly1-S cells (Figure S5H). TCF3 binding sites were confirmed to be present within 
putative enhancer regions of PRKAR2B in a B cell context, based on the analysis of 
chromatin immunoprecipitation data available for the GM12878 line (ENCODE Project 
Consortium, 2012) and regions of open chromatin in our manipulated OCI-Ly1 lines (Figure 
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S5I). Conversely, overexpression of PRKAR2B or PRKAA2, which we observed to provide 
survival advantage to OCI-Ly1, SU-DHL4 and SU-DHL6 lines following venetoclax (Figure 
2G, Figure S5J-S5K), led to reduced ID2 and ID3 proteins (Figure 6D-6E. Confirming the 
involvement of cellular energy metabolism in this circuit, venetoclax sensitivity of the 
PRKAA2 and PRKAR2B overexpressing cells was restored by either dorsomorphin or 
oligomycin (Figure 6F, Figure S5L). Finally, single cell clones derived from the ID3 
knockout cell line (Figure S5M) exhibited greater sensitivity to the combination of 
venetoclax and either dorsomorphin or oligomycin than control cells (Figure 6G). These 
observations link the results of each screen and identify a venetoclax resistance circuit 
involving AMPK dependency and mitochondrial respiratory-chain adaptations related to ID3 
repression and PRKAR2B overexpression.
MCL-1 and AMPK deregulation drive venetoclax resistance in patients
To determine if there was a genetic basis for the observed drug resistance in the OCI-Ly1-R 
cells, we compared the results of WES of DNA isolated from the OCI-Ly1-R and OCI-Ly1-
S cell lines. No non-silent sSNVs overlapping with our screen data were identified except in 
BCL2, a target of aberrant somatic hypermutation frequently affected in B lymphomas and 
most B-cell lines (Table S8) (Chapuy et al., 2018). However, none involved the BH3 domain 
residues previously linked to venetoclax resistance in cell lines or in patients (Blombery et 
al., 2018; Fresquet et al., 2014). Regarding sCNVs, a clear region was amplified on 
chromosome 1q23 (amp[1q]) in the OCI-Ly1-R but not in the OCI-Ly1-S cells. No other 
differential sCNVs were identified (Figure 7A, Figure S6A).
In line with the cell line data, we observed growing subclones with amp(1q) in 4 of 6 
aforementioned cases with venetoclax-resistant CLL (Patients 1, 2, 3 and 4; Figures 1B, 7B, 
Tables S1-S4). We confirmed a common region of gain of 8 Mb amongst the resistant cell 
line and Patients 1, 2, and 3. Contained within this amplified region were several genes of 
interest including MCL1 and PRKAB2, encoding a regulatory subunit of AMPK (Figure 
7C). To confirm the involvement of MCL-1 overexpression and AMPK signaling in patients, 
we investigated changes in protein expression by immunohistochemistry staining on 
biopsies obtained from 5 of 6 patients (Patients 2-6) for which pre- and post-venetoclax 
tissues were available. We extended this cohort to include tissues from 4 additional CLL 
patients with relapsed disease following venetoclax (Patients A-D) (Tables S1 and S2, 
Figure S6B). As expected, MCL-1 and AMPK were expressed at higher levels on formalin-
fixed OCI-Ly1-R cells than on OCI-Ly1-S cells, and furthermore, we observed elevated 
expression of the downstream target of AMPK, acetyl-CoA carboxylase (ACC) and its 
phosphorylated form (p-ACC) on the resistant cell line (all p < 0.03, Figure S6C). In patient 
tissue samples, we detected increased MCL-1 expression in post-venetoclax tissue samples 
from 6 of 9 patients (Pt 2, 3, 5, A, B and C) (all p = or < 0.026), but also that pre-treatment 
tissues from Patients 4, 6 and D already exhibited elevated MCL-1 expression (Figure 7D). 
In our series, high pretreatment MCL-1 expression (>10% of positive cells) was associated 
with shorter progression-free survival (p= 0.017, Figure 7E); these findings support further 
evaluation of this association in larger cohorts. Elevations in AMPK expression with relapse 
were clearly evident for Patients 2, 6, A and C (all p = or < 0.0062) and AMPK signaling 
activation was supported by the observations of increased ACC and p-ACC in tissue from 
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Patients 2, 4, 6 and C (Figure 7D). In line with our cell line data implicating a resistance 
circuit involving overexpression of AMPK and reduction of ID3, quantitative PCR of RNA 
extracted from formalin-fixed tissue from 3 of 3 paired patient samples (Pts 2, 5 and 6) 
revealed decreased relative expression of ID3 in association with relapse (p< or =0.0001, 
Figure 7F). These results support the involvement of both MCL-1 and AMPK in venetoclax 
resistance in CLL patient samples with acquired venetoclax resistance and reveal a genetic 
basis for MCL-1 and AMPK overexpression.
DISCUSSION
Diversity within a cancer cell population has been shown to fuel clonal evolution and 
subsequent therapeutic resistance. In line with that model, our study implicates major clonal 
shifts and heterogeneous evolutionary trajectories in patients with CLL relapsing on 
venetoclax, thereby involving multiple potential means of escape.
Discrete mutations in the gene targets of therapeutic inhibitors have been long-identified as a 
common mechanism of resistance to targeted therapies (Ellis and Hicklin, 2009; Gorre et al., 
2001; Woyach et al., 2014). Recently, a BCL2 mutation impairing the venetoclax binding 
site of BCL-2 was described in a small cohort of CLL patients relapsing on venetoclax 
(Blombery et al., 2018). However, this mutation was commonly detected at only subclonal 
levels in this series, and was found in only a subset of patients, suggesting the presence of 
alternative non-mutational mechanisms of resistance to venetoclax. Indeed, neither we nor a 
previous study (Herling et al., 2018) detected this mutation.
Our systematic characterization of venetoclax resistance revealed dramatic alterations in the 
expression profiles of cells and complex genomic changes. On the one hand, our aggregate 
results underscore that alterations leading to overexpression of MCL-1, and thus the ability 
to sequester BIM and therefore to compensate BCL-2 inhibition, is a consistent adaptive 
mechanism of resistance for this class of BCL-2 inhibitor (Konopleva et al., 2006; Lin et al., 
2016; Yecies et al., 2010). We detected MCL-1 overexpression and amplification in patient 
samples, not previously reported. On the other hand, our genome-wide screens together with 
functional characterization of resistant cell lines have uncovered deregulated energy 
metabolism via altered expression of components of the AMPK signaling pathway in this 
process. In support of the notion of a dual impact of venetoclax on the mitochondria, we 
notably identified a recurrence of amp(1q23), encompassing both MCL1 and the AMPK 
pathway component PRKAB2 in both representative cell lines and patient samples. Our 
work thus characterizes venetoclax resistance as involving both reprogramming of the 
biology of the mitochondria outer membrane, leading to expression changes in BCL-2 
family members, as well as increased OXPHOS activity which is resident in the organelle’s 
inner membrane (Figure 7G). We note however, that other important mechanisms could be 
also involved, and could include other energy pathways, lymphoid differentiation, 
endoplasmic reticulum, mitochondrial biogenesis or mitophagy.
Our findings thus demonstrate that venetoclax imposes a broader scope of ‘mitochondrial 
stress’ than previously suggested. In AML, leukemia stem cells have dependency on 
oxidative phosphorylation which can be efficiently targeted by BCL-2 inhibition (Jones et 
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al., 2018; Lagadinou et al., 2013; Pollyea et al., 2018). We confirm that venetoclax also 
targets OXPHOS in lymphoid malignancies. Furthermore, our study reveals that increased 
OXPHOS is a resistance mechanism to BCL-2 inhibition, a finding of potential relevance to 
other malignancies as well. Our work adds to the growing evidence of crosstalk between the 
BCL-2 family and the ETC. Early studies demonstrated that even prior to downstream 
activation of caspases, the apoptosis program results in a relatively rapid defect in the ETC 
(Mootha et al., 2001). Maintenance of ETC integrity was recently shown to allow cells to 
proliferate after apoptosis induction (Jiang et al., 2016). Conversely, the BCL-2 family 
proteins can participate in non-apoptotic functions such as regulation of mitochondrial 
morphology, autophagy or metabolism (Chen and Pervaiz, 2007; Lagadinou et al., 2013; 
Giménez-Cassina and Danial, 2015; Gross and Katz, 2017). Our data support the notion that 
venetoclax perturbs the cellular respiration process through the process of mitochondrial 
outer membrane permeabilization, leading to the release of cytochrome c, a crucial 
component of the inner membrane (Figure 7G).
We further find that the regulation of such optimized metabolism depends on repression of 
the ID family of lymphoid transcriptional regulators. These results mesh well with recent 
work demonstrating that lymphoid transcription factors function as metabolic gatekeepers by 
limiting the amount of cellular ATP to levels that are insufficient for malignant 
transformation (Chan et al., 2017). Hence, although our studies focused on the impact of 
ID3, a broader involvement of altered lymphoid differentiation state on venetoclax resistance 
is anticipated since reduction of additional lymphoid transcription factors (IKZF5, EP300) 
were identified in our knockout screen.
These insights have the potential to provide therapeutic opportunities. We point out that 
mutations affecting these factors have been detected across B-cell malignancies, and thus we 
expect them to confer venetoclax resistance. Our findings may therefore guide the further 
development of BCL-2 inhibitors in diseases lacking these mutations. Our data support the 
idea that targeting MCL-1 with emerging inhibitors would be a rationale and effective way 
to counteract venetoclax resistance. Given the association with higher OXPHOS status with 
resistance, this adaptive activity can be exploited to overcome venetoclax resistance. Our 
study further casts light on the mechanisms underlying diverse strategies previously 
evaluated to overcome resistance to BCL-2 inhibition, which have included hypoxia, caloric 
restriction (Meynet et al., 2013) and the use of the kinase inhibitors (including AMPK) 
(Kerkela et al., 2009; Oppermann et al., 2016) or mitochondrial ETC modulators 
(Chukkapalli et al., 2018).
STAR METHODS TEXT
Lead Contact and Materials Availability
Further information and requests for resources and reagents should be directed to and 
fulfilled by the Lead Contact, Catherine J Wu (cwu@partners.org). This study did not 
generate new unique reagents.
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Experimental Model and Subject Details
Animals—Eight-week old (at time of transplant) female NSG (strain name: NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) were used for in vivo studies. Randomization prior to treatment 
was performed according to tumor measurements by caliper. Weight of animals was 
monitored thrice weekly throughout the treatment. All animals were housed at Dana-Farber 
Cancer Institute (DFCI). All animal procedures were completed in accordance with the 
Guidelines for the Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committees at DFCI.
OCI-Ly1 xenografts were generated in 30 NSG mice that were injected subcutaneously into 
the left flank with 5×106 OCI-Ly1 cells per animal, resuspended 1:1 in PBS:Matrigel 
(Sigma-Aldrich). Tumors were measured by caliper twice weekly, starting one week after 
transplant, and volumes calculated according to the formula: LxW2/2. Animals were 
randomized for treatment on day 10 post-transplant (median 93-122 mm3 in each group; 
animals with tumors <30 mm3 were not included in the treatment study), and assigned to the 
four treatment cohorts (6-7 mice/group) receiving either vehicle control; 200 μg/kg 
oligomycin-A (Sigma-Aldrich) in PBS-10% ethanol; 25 mg/kg venetoclax (LC 
Laboratories) in 60% phosal 50 propylene glycol, 30% propylene glycol 400 and 10% 
ethanol (Souers et al., 2013) or their combination, for 20 days. Tumors were measures twice 
weekly throughout treatment.
Human Samples—Specimens were collected from CLL patients enrolled on clinical trials 
of venetoclax treatment (Patients 1-5, A and C from ; Patients 6 and B from ) or from 
general practice (Patients D and 7-16), conducted in accordance with the principles of the 
Declaration of Helsinki and with the approval of the Institutional Review Boards (IRB) of 
the University of Texas M.D. Anderson Cancer Center (MDACC; Patients 1, 3, 4) or of 
Dana-Farber Cancer Institute (DFCI; Patient 2, 5-16, A-D). Informed consent was obtained 
from all subjects. Their clinical characteristics are reported in Table S1. For patient 1-6, 
blood and/or tissue tumor samples were collected at baseline, before initiation of venetoclax 
therapy, and at relapse or progression on venetoclax (Table S2). For both PBMC (unsorted) 
or tissue, we first confirmed that the tumor purity was >80% by flow cytometry or 
immunohistochemistry. Genomic DNA (patient 1-6) was isolated with the DNAeasy Blood 
and Tissue Kit (Qiagen). Total RNA was purified from formalin-fixed, paraffin-embedded 
tissue sections with the RNeasy FFPE Kit (Qiagen). For patient 7-16, fresh CLL cells were 
isolated from peripheral blood using the Ficoll method.
Microbe Strains—NEB-5alpha Competent E. coli were transformed based on the high 
efficiency transformation protocol and grown on plates of LB agar with ampicillin 100 
microg/mL for plasmid selection at 37°C.
Cell Lines—OCI-Ly1 cells (male) were cultured in Iscove's Modified Dulbecco's Media 
(Gibco) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin/
glutamine. Cell lines resistant to venetoclax were generated over 10 weeks by exposing the 
cells to increasing doses of venetoclax starting at 10 nM, and then doubling this dose when 
the cells were able to grow at a rate equivalent to the parental lines until the cells were able 
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to tolerate 1 μM of venetoclax. SU-DHL4 (male), SU-DHL6 (male) and Toledo (female) 
cells were cultured in Roswell Park Memorial Institute media (Gibco) supplemented with 
10% FBS and 1% penicillin/streptomycin. All cell lines were incubated at 37°C.
Primary Cell Culture—Isolated CLL cells from patients described in the human samples 
section (patient 7-16, Table S1) were cultured in Roswell Park Memorial Institute media 
(Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin for in vitro drug 
testing. Samples were collected in accordance with the principles of the Declaration of 
Helsinki and with the approval of the Institutional Review Boards (IRB) of Dana-Farber 
Cancer Institute. Informed consent was obtained from all subjects.
Method Details
Cell viability assay—The Cell Titer-Glo Luminescent Cell Viability Assay (Promega) 
was used to determine the relative number of viable cells after drug treatment. 0.2 × 106 
cells/mL were seeded in a 24 well-plate and treated with drugs for 24 or 48 hours. The 
viability assay was conducted using the manufacturer’s protocol after treatment. Values were 
normalized to DMSO-treated cells. Plates were read on a SpectraMax M3 reader (Molecular 
Devices).
Western blotting—Total protein from cells was isolated using RIPA Buffer (20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium 
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM ß-glycerophosphate, 1 mM Na3VO4, 1 
μg/mL leupeptin), supplemented with protease inhibitors (Thermo Fisher Scientific) and 
phosphatase inhibitors (Thermo Fisher Scientific). Protein concentration was determined 
with the BCA Protein Assay (Pierce). Protein samples (25 μg) were separated on either 
4-12% Bis-Tris gels (proteins <250 kDa) or Tris-acetate gels (proteins >250 kDa). Protein 
was transferred to a nitrocellulose or PVDF membrane (Life Technologies) using the iBlot2 
system (Life Technologies). Membranes were incubated overnight with primary antibodies. 
After incubation in the appropriate secondary antibodies, protein was detected using 
chemiluminescence (Western Lightning Plus-ECL, Perkin Elmer).
Genome-scale screens
Conduct of the genome-wide CRISPR-screen: The strategy used was similar in approach 
as previously reported (Shalem et al., 2014). 300 × 106 Cas9-OCI-Ly1 cells were suspended 
in media supplemented with 8 μg/mL polybrene and seeded into 9 12-well plates (1 mL per 
well). Titration of the dose of puromycin and of polybrene on OCI-Ly1 cells was undertaken 
to achieve 100% and minimal death of non-infected cells, respectively. The BRUNELLO 
sgRNA viral library in lentiGuide-puro (Genetic Perturbation Platform, Broad Institute) was 
added to each well (200 μL/mL), titrated to achieve an infection rate of 30% without 
excessive cell death and to minimize multiplicity of infection. The plates were spun at 2000 
rpm for 2 hr at 37°C and incubated at 37°C for 24 hr. Polybrene was diluted by adding 2 mL 
of standard media to each well. Puromycin selection (1 μg/mL) was initiated 48 hours post-
transduction and sustained for 5 days. Two days after puromycin selection, transduced OCI-
Ly1 cells were treated with venetoclax (100 nM -- a dose identified to be growth suppressive 
at day 14) or DMSO as control for 14 days in T225 flasks. Cells were counted and re-split 
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every three days, maintaining a concentration of 200,000 cells/mL Approximately 40 
million cells were frozen before and after venetoclax or DMSO selection for sequencing. 
This experiment was performed in duplicates.
Genomic DNA was isolated (Maxiprep kits, Qiagen), and PCR and barcoded sgRNA or 
ORF-sequencing were performed, as previously described.(Doench et al., 2016) Samples 
were sequenced on a HiSeq2000 (Illumina). For analysis, the read counts were normalized 
to reads per million and then log2 transformed. The log2 fold-change of each sgRNAs was 
determined relative to the initial time point for each. Significance of the sgRNAs’ 
enrichment was assessed using the STARS software (v1.3, Broad Institute).
Conduct of the genome-wide ORF-screen: The approach used was based on previous 
reports (Johannessen et al., 2013; Rotem et al., 2015). Optimal transduction conditions were 
determined in order to achieve 30-50% infection efficiency, corresponding to a multiplicity 
of infection (MOI) of ~0.5 - 1. Briefly, 1.5 × 106 of OCI-Ly1 cells were spun-infected in 6 
wells of a 12-well plates with different virus volumes. The day after, OCI-Ly1 cells were 
seeded in 2 wells of a 6-well plate, each with complete medium, one supplemented with 1 
μg/mL of puromycin. Cells were counted 4 days postselection to determine the infection 
efficiency, comparing survival with and without puromycin selection. Volumes of virus that 
yielded ~30 - 50% infection efficiency were used for screening.
We used an ORFeome barcoded library that contains 17,255 barcoded ORFs overexpressing 
12,952 unique genes (Broad Institute). Large-scale infections were performed in 12-well 
format as the viral titration described above using the optimized volume of virus, and pooled 
24 hours post-centrifugation. Infections were performed with an adequate number of cells to 
achieve a representation of at least 1000 cells per ORF following puromycin selection (~2 × 
107 surviving cells containing 17,255 ORFs). ~24 hours after infection, all wells within a 
replicate were pooled and were split into T225 flasks. 48 hours after infection, cells were 
selected with puromycin for 72 hours to remove uninfected cells. Seventy-two hours after 
selection, OCI-Ly1 cells were treated with either DMSO or 100 nM venetoclax and passaged 
in fresh media containing either DMSO or drug every 3-4 days. Cells were harvested 10 
days after initiation of treatment. Isolation of genomic DNA, sequencing and analyses were 
performed as for the CRISPR-Cas9 screen. The log2 fold-change of each ORF was 
determined relative to the initial time point for each. This experiment was performed in 
duplicates.
Generation of CRISPR-Cas9 engineered isogenic cell lines and 
overexpression cell lines
Cloning of sgRNA vectors: Two of 4 sgRNAs per target were selected from the 
BRUNELLO genome-scale library (based on highest levels of representation from the 
genome-wide screen) and related DNA oligonucleotides were synthesized (Gene Link; Table 
S5), along with oligonucleotides corresponding to 2 control non-targeting sgRNAs per gene. 
Oligonucleotides were phosphorylated and annealed using T4 PNK (New England Biolabs). 
The backbone vector (pLKO5.sgRNA.EFS.GFP) (Addgene Plasmid #57822) (Heckl et al., 
2014) was digested with FastDigest BsmBI (Thermo Scientific), and the vector and 
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oligonucleotides were ligated with T7 DNA ligase (New England Biolabs). The ligation 
reaction was treated with Plasmid-Safe exonuclease (Epicentre) to prevent unwanted 
recombination products. The final product (1 μL) was transformed into 25 μL of DH5α 
competent cells (New England Biolabs). Colonies were selected and sequenced before 
undergoing plasmid DNA extraction (Endotoxin-Free Plasmid Maxiprep, Qiagen).
Cloning of ORFs vectors: The ORFs for PRKAR2B and PRKAA2 (clone ID: 
TRCN0000480583 and TRCN0000492160, respectively; Broad Institute Genetic 
Perturbation Platform ORFeome library (https://portals.broadinstitute.org/gpp/public/)) were 
cloned into the pLX_TRC317. This is a lentiviral expression vector that encodes a 
puromycin resistance cassette and an ORF expression cassette under control of the EF1-
alpha promoter.
Generation of a Cas9 overexpressing cell line: Stable Cas9-expressing OCI-Ly1 and SU-
DHL4 cells were generated by transducing parental cells with lentivirus prepared with 
lentiCas9-Blast pXR101 (Addgene plasmid # 52962) (Sanjana et al., 2014) encoding Cas9 
and blasticidin resistance. Selection with blasticidin (10 μg/mL) was initiated 48 hr after 
transduction and sustained throughout culture of Cas9-expressing cell lines. Cas9 activity 
was checked as previously reported by using the pXPR-011 vector (Addgene plasmid # 
59702) (Doench et al., 2014).
Lentivirus production and purification: To produce lentivirus, ~800,000 HEK293T cells 
were seeded per well in a 6-well plate in 2.7 mL of antibiotic-free DMEM supplemented 
with 10% FBS. For each well, 150 μL of OptiMEM (Life Technologies) was mixed with 5 
μg of pLKO5_sgRNA plasmid, 0.4 μg of pVSV.G (Addgene #12259), and 1.5 μg of psPAX2 
(Addgene #12260). Separately, 9 μl of Lipofectamine 2000 (Life Technologies) was diluted 
in 150 μl OptiMEM. After a 15 min incubation at room temperature, the DNA and 
Lipofectamine mixes were combined and incubated together at room temperature for 30 min 
before being added to the cells. After 12 hr, the media was changed to DMEM supplemented 
with 20% FBS. 48 hr post-transfection, 3 mL of media was removed and filtered through a 
0.45 μm low protein binding membrane (Millipore Steriflip HV/PVDF) and added to 1 mL 
of LentiX Concentrator (Clontech). This mixture was then incubated at 4°C for 2 h, and 
centrifuged at 1500×g for 45 min at 4°C. The pellet was resuspended in 100 μL of PBS and 
stored in aliquots at −80°C.
Generation of engineered cell lines: 0.5 × 106 target cells (OCI-Ly1, SU-DHL4, SU-
DHL6) were suspended in media supplemented with 8 μg/mL polybrene and seeded into 6-
well plates (1 mL per well), to which lentivirus was added (50 μL/mL to each well). The 
plates were spun at 2000 rpm for 2 hr at 37°C and incubated at 37°C for 24 hr. The 
polybrene-containing media was then replaced by 2 mL of fresh media per well. After 3 
days, transduced cells were selected (i.e. by puromycin (1 μg/mL for OCI-Ly1, 0.5 μg/mL 
for SU-DHL4 and SU-DHL6) for 1 week for the ORF-overexpressing cells) or sorted (i.e. 
based GFP or mCherry expression for the CRISPR gene-edited lines) and cryopreserved for 
further experiments. As confirmation that the engineered cell lines expressed the expected 
alterations, we: (i) evaluated the expression of the targeted protein by western-blotting 
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(Figure S2E-F, Figure S5D-J), and (ii) for the CRISPR-Cas9 engineered cell lines, 
performed targeted DNA sequencing for the CRISPR target sites before and after 2 weeks of 
exposure to venetoclax (100 nM), and assessed the proportion of frameshift indels (Figure 
S2I). In brief, we used a two-step touchdown PCR protocol. Genomic DNA from the pre- 
and post-treated samples was PCR-amplified using KAPA HiFi DNA polymerase and 
primers specific for the target sequence of the sgRNAs. Products from the first reaction were 
barcoded with Illumina sequencing adaptor sequences and indexes during a second round of 
PCR. Following PCR, samples were purified with Agencourt AMPure XP beads (Beckman 
Coulter) and quantified on a Bioanalyzer (Agilent) with High Sensitivity DNA chips. 
Sample libraries were diluted to 4 nM, pooled, and ran on the Illumina MiSeq platform 
using single-end sequencing with the following parameters: read 1: 296nt, index 1: 6nt.
Single-cell cloning of the ID3 knockout OCI-Ly1 cells was performed using dose-limiting 
dilution strategy. Cells from the bulk ID3 OCI-Ly1 were seeded at a concentration of 0.5 
cells/well in a 96-well plate (5 plates per cell line). To investigate the presence of mutations, 
6 clones per sgRNA were analyzed by PCR and Sanger sequencing using primers flanking 
the target sites for the sgRNAs. The absence of ID3 protein were confirmed in clones 
harboring loss-of-function mutations by western blot (Figure S5M). Three different 
knockout single-cell clones for each sgRNA were used for further functional studies.
Generation of OCI-Ly1 Double-knock out for BAX and BAK1: To achieve stable down-
regulation of both BAX and BAK proteins in the OCI-Ly1 cell line, a two-step transduction 
and selection process was performed. First, OCI-Ly1 cells were transduced with lentivirus 
expressing sgRNA targeting BAX (5’-TCGGAAAAAGACCTCTCGGG-3’), together with a 
GFP marker, selected by cell sorting after 5 days, and cultured in vitro for at least a week 
before western blot assessment of successful BAX targeting; then, the cell line was further 
transduced with lentivirus expressing sgRNA targeting BAK1 (5’-
GCTCACCTGCTAGGTTGCAG-3’), together with an mCherry marker. Five days after 
transduction, double-positive cells were sorted, and cultured for 8 days before assessment of 
protein expression by Western Blot. A similar two-step transduction was obtained in the 
OCI-Ly control line, transduced with non-targeting sgRNA-expressing lentivirus (one 
carrying GFP, one carrying mCherry).
Whole-exome sequencing and data analyses—Library construction from CLL and 
matched germline DNA of Patients 1–6 was performed as previously described (Fisher et al., 
2011), with the following modifications: (i) initial genomic DNA input into shearing was 
reduced from 3 μg to 10–100 ng in 50 μl of solution; (ii) for adapter ligation, Illumina 
paired-end adapters were replaced with palindromic forked adapters (from Integrated DNA 
Technologies), with unique dual-indexed molecular barcode sequences included in the 
adapter sequence to facilitate downstream pooling. With the exception of the palindromic 
forked adapters, the reagents used for end repair, A-base addition, adapter ligation and 
library enrichment PCR were purchased from KAPA Biosciences in 96-reaction kits, (iii) 
during the post-enrichment solid-phase reversible immobilization (SPRI) cleanup, elution 
volumes were reduced to 30 μL to maximize library concentration, and a vortexing step was 
added to maximize the amount of template eluted. Any libraries with concentrations below 
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40 ng/ml (per PicoGreen assay, automated on an Agilent Bravo) were considered failures 
and reworked from the start of the protocol. Following library construction, hybridization 
and capture were performed using the relevant components of Illumina’s Nextera Rapid 
Capture Exome Kit and following the manufacturer’s suggested protocol. with the following 
exceptions: first, all libraries within a library construction plate were pooled prior to 
hybridization. Second, the Midi plate from Illumina’s Nextera Rapid Capture Exome Kit 
was replaced with a skirted PCR plate to facilitate automation. All hybridization and capture 
steps were automated on the Agilent Bravo liquid handling system. After post-capture 
enrichment, library pools were quantified using qPCR (automated assay on the Agilent 
Bravo), using a kit purchased from KAPA Biosystems with probes specific to the ends of the 
adapters. On the basis of qPCR quantification, libraries were normalized to 2 nM, and then 
denatured using 0.1N NaOH on the Hamilton Starlet. After denaturation, libraries were 
diluted to 20pM using hybridization buffer purchased from Illumina.
Cluster amplification of denatured templates was performed according to the manufacturer’s 
protocol (Illumina) using HiSeq 4000 cluster chemistry and HiSeq 4000 flowcells. The 
flowcells are then analyzed using RTA v.1.18.64 or later. Each pool of whole exome libraries 
was run on paired 76bp runs, reading the dual-indexed sequences to identify molecular 
indices and sequenced across the number of lanes needed to meet coverage for all libraries 
in the pool.
Alignments to hg19 using bwa version 0.5.9-r16 (Li and Durbin, 2010) and quality control 
were performed using the Picard (http://picard.sourceforge.net/) and Firehose (pipelines at 
the Broad Institute). Firehose is a framework combining workflows for the analysis of 
cancer-sequencing data. The workflows perform quality control, local re-alignment, 
mutation calling, small insertion and deletion identification, rearrangement detection and 
coverage calculations, among other analyses. Average coverage and quality control metrics 
are listed in Table S3.
Identification of somatic mutations: Sequencing output was processed with the Picard and 
GATK toolkits developed at the Broad Institute, a process that involves marking duplicate 
reads, recalibrating base qualities and realigning around somatic small insertions and 
deletions (sINDELs). All BAM files were generated by aligning with bwa version 0.5.9 to 
the NCBI Human Reference Genome Build hg19. Prior to variant calling, the impact of 
oxidative damage (oxoG) and FFPE damage to DNA during sequencing was quantified 
according to Costello et al. (Costello et al., 2013). The cross-sample contamination was 
measured with ContEst based on the allele fraction of homozygous SNPs (Cibulskis et al., 
2011), and this measurement was used in MuTect. From the aligned BAM files, somatic 
alterations were identified using a set of tools developed at the Broad Institute 
(www.broadinstitute.org/cancer/cga). The details of our sequencing data processing have 
been described elsewhere (Berger et al., 2011; Chapman et al., 2011).
Following our standard procedure, sSNVs were detected using MuTect (version 1.1.6) 
(Cibulskis et al., 2013); sINDELs were detected using Strelka (Saunders et al., 2012). We 
then applied a stringent set of filters to improve the specificity of our sSNV and sINDEL 
calls and remove likely FFPE artifacts. We applied an allele fraction specific panel-of-
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normals filter, which compares the detected variants to a large panel of normal exomes and 
removes variants that were observed in the panel-of-normals. We then applied a realignment 
based filter, which removes variants that can be attributed entirely to ambiguously mapped 
reads. All filtered events in candidate CLL genes were also manually reviewed using the 
Integrated Genomics Viewer (IGV) (Robinson et al., 2011). In the matched sample sets from 
6 individuals, we utilized “forced calling” to quantify the number of reads supporting the 
alternate and reference alleles at sites which were detected in any sample from that 
individual. Estimation of and correction for tumour contamination in normal was performed 
using the deTiN algorithm (Taylor-Weiner et al., 2018) to recover somatic mutations that 
would have otherwise been filtered out due to evidence of the mutation in the normal. To 
address the lack of a matched normal sample (in Patient 3) we used a stringent panel-of-
normals and population allele frequency criteria, and excluded non-coding variants from 
analysis. To address the lack of a matched normal sample (in Patient 6), we used a stringent 
panel-of-normals and population allele frequency criteria, and excluded non-coding variants 
from analysis. Furthermore, parental OCI-Ly1-S cells were used as a source control DNA in 
order to highlight sSNVs that were acquired in the resistant OCI-Ly1-R cells. Reference lists 
for sSNVs and sINDELs in known putative CLL driver genes as well as for recurrent CNAs 
were concatenated based on previous sequencing studies of large CLL cohorts (Wang et al., 
2011; Quesada et al., 2012; Landau et al., 2013; Puente et al., 2015; Landau et al., 2015). 
Total copy number was measured using ReCapSeg (Ramos et al., 2015), then segmented into 
allelic copy number with AllelicCapSeg (Stachler et al., 2015) based on heterozygous 
germline sites detected with HaplotypeCaller according to the protocol described previously 
(http://archive.broadinstitute.org/cancer/cga/acsbeta).
Estimation of mutation cancer cell fraction using ABSOLUTE and clonal evolution 
mapping: The cancer cell fraction (represented as a probability density distribution ∈ [0, 1]) 
of individual somatic alterations were estimated using the ABSOLUTE algorithm (v1.5) 
which calculates the sample purity, ploidy, and local absolute DNA copy-number of each 
mutation, as previously described (Carter et al., 2012; Landau et al., 2013). CCFs were 
clustered as previously described (Landau et al., 2013) to delineate distinct subclonal 
populations. Phylogenetic relationships between these populations were inferred using 
patterns of shared mutations and CCF using the PhylogicNDT analysis (Leshchiner et al., 
2018).
RNA sequencing
cDNA Library Construction: Total RNA was quantified using the Quant-iT™ 
RiboGreen® RNA Assay Kit and normalized to 5 ng/μl Following plating, 2 μL of ERCC 
controls (using a 1:1000 dilution) were spiked into each sample. An aliquot of 200ng for 
each sample was transferred into library preparation which uses an automated variant of the 
Illumina TruSeq™ Stranded mRNA Sample Preparation Kit. This method preserves strand 
orientation of the RNA transcript. It uses oligo dT beads to select mRNA from the total RNA 
sample, followed by heat fragmentation and cDNA synthesis from the RNA template. The 
resultant 400bp cDNA then goes through dual-indexed library preparation: ‘A’ base 
addition, adapter ligation using P7 adapters, and PCR enrichment using P5 adapters. After 
enrichment, the libraries were quantified using Quant-iT PicoGreen (1:200 dilution). After 
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normalizing samples to 5 ng/μL, the set was pooled and quantified using the KAPA Library 
Quantification Kit for Illumina Sequencing Platforms.
The entire process was in a 96-well format and all pipetting is done by either Agilent Bravo 
or Hamilton Starlet.
Illumina Sequencing: Pooled libraries were normalized to 2 nM and denatured using 0.1 N 
NaOH prior to sequencing. Flowcell cluster amplification and sequencing were performed 
according to the manufacturer’s protocols using either the HiSeq 2000 or HiSeq 2500 
instrument. Each run generated a 101bp paired-end with an eight-base index barcode read. 
Data was analyzed using the Broad Picard Pipeline, which includes de-multiplexing and data 
aggregation.
Data analyses: RNA-seq data were aligned to GRCh38.p5 with STAR-2.5.1b (Dobin et al., 
2013). Gene expression was quantified with RSEM-1.2.31 (Li and Dewey, 2011). DESeq2 
(Love et al., 2014) was applied to call differentially expressed genes between each cell line 
and control group. Pathway enrichment analysis was performed with GSEA (Subramanian et 
al., 2005) in GenePattern (Reich et al., 2006).
Mass spectrometry-based proteome investigations
In Solution Digestion: OCI-Ly1 cell pellets were lysed at 4 °C in 8 M urea, 50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2 μg/μl aprotinin (Sigma-Aldrich), 10 μg/μl 
leupeptin (Roche), and 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma). Protein 
concentration was determined using a bicinchoninic acid (BCA) protein assay (Pierce). 
Proteins were reduced with 5 mM (DTT) for 45 min at room temperature (RT), followed by 
alkylation with 10 mM iodoacetamide for 30 min at room temperature in the dark. Urea 
concentration was reduced to 2 M with 50 mM Tris-HCl, pH 8. Samples were pre-digested 
for 2 hr at 30 °C with endoproteinase Lys-C (Wako Laboratories) at an enzyme-to-substrate 
ratio of 1:50. Samples were digested overnight at 37°C with sequencing grade trypsin 
(Promega) at an enzyme-to-substrate ratio of 1:50. Following overnight digest, samples were 
acidified with neat formic acid to a final concentration of 1%. Acidified samples were 
subsequently desalted on a 100 mg tC18 Sep-Pak SPE cartridge (Waters). Briefly, cartridges 
were conditioned with 1 mL of 100% MeCN, 1 mL of 50% MeCN/0.1% FA, and 4x with 1 
mL of 0.1% TFA. The sample was loaded, and washed 3x with 1 mL of 0.1% TFA, 1x with 
1 mL of 1% FA, and eluted 2x with 600 μl of 50% MeCN/0.1% FA. Following desalting, 
100 μg of the sample was dried to completion and stored at −80 °C.
TMT labeling of peptides: Desalted peptides were labeled with TMT 10-plex isobaric mass 
tagging reagents (Thermo Fisher Scientific) as previously described (Mertins et al., 2018). 
Each TMT reagent was resuspended in 41 μL of MeCN. Peptides were resuspended in 100 
μL of 50 mM HEPES and combined with TMT reagent. Samples were incubated at RT for 1 
hr while shaking. The TMT reaction was quenched with 8 μL of 5% hydroxylamine at RT 
for 15 min with shaking. TMT labeled samples were combined, dried to completion, 
reconstituted in 100 μL of 0.1% FA, and desalted on StageTips or 100 mg SepPak columns 
as described above.
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Basic Reverse Phase (bRP) Fractionation: The TMT labeled samples were fractionated 
using offline high pH reversed-phase chromatography (bRP) as previously described 
(Mertins et al., 2018). Samples were fractionated using Zorbax 300 Extend C18 column (4.6 
× 250 mm, 300 Å, 5 μm, Agilent) on an Agilent 1100 series high-pressure liquid 
chromatography (HPLC) system. Samples were reconstituted in 900 μL of 5 mM 
ammonium formate (pH 10.0)/2% (vol/vol) acetonitrile (MeCN) (bRP solvent A). Samples 
were injected with Solvent A at a flow rate of 1 mL/min and separated using a 96 min 
gradient. The gradient consisted of an initial increase to 16% solvent B (90% MeCN, 5 mM 
ammonium formate, pH 10), followed by 60 min linear gradient from 16% solvent B to 40% 
B and successive ramps to 44% and 60% at a flow rate of 1 mL/min. Fractions were 
collected in a 96-deep well plate (GE Healthcare) and pooled in a non-contiguous manner 
into final 24 proteome fractions. Pooled fractions were dried to completeness using a 
SpeedVac concentrator.
Liquid chromatography and mass spectrometry: Desalted peptides were resuspended in 
9 μL of 3% MeCN/0.1% FA and analyzed by online nanoflow liquid chromatography 
tandem mass spectrometry (LC-MS/MS) using Q-Exactive + mass spectrometer (Thermo 
Fisher Scientific) coupled on-line to a Proxeon Easy-nLC 1200 (Thermo Fisher Scientific) 
as previously described (Mertins et al., 2018). Briefly, 4 μL of each sample was loaded onto 
a microcapillary column (360 μm outer diameter × 75 μm inner diameter) containing an 
integrated electrospray emitter tip (10 μm), packed to approximately 22 cm with ReproSil-
Pur C18-AQ 1.9 μm beads (Dr. Maisch GmbH) and heated to 50 °C. Samples were analyzed 
with 110 min method. The 110 min method contained a mobile phase with a flow rate of 200 
nL/min, comprised of 3% acetonitrile/0.1% formic acid (Solvent A) and 90% acetonitrile /
0.1% formic acid (Solvent B), with the following gradient profile: (min:%B) 0:2; 1:6; 85:30; 
94:60; 95:90; 100:90; 101:50; 110:50 (the last two steps at 500 nL/min flow rate). The Q-
Exactive+ MS was operated in the data-dependent mode acquiring HCD MS/MS scans (r = 
35,000) after each MS1 scan (r = 70,000) on the 12 most abundant precursor ions using an 
MS1 target of 3 × 106 and an MS2 target of 5 × 104. The maximum ion time utilized for 
MS/MS scans was 120ms; the HCD-normalized collision energy was set to 30; the dynamic 
exclusion time was set to 20 s, isotope exclusion function was enabled, and peptide match 
function was set to preferred. Charge exclusion was enabled for charge states that were 
unassigned, 1 and >6.
Data Analysis: All data were analyzed using Spectrum Mill software package v 6.1 pre-
release (Agilent Technologies). Similar MS/MS spectra acquired on the same precursor m/z 
within +/− 60 s were merged. MS/MS spectra were excluded from searching if they were not 
within the precursor MH+ range of 750-4000 Da or if they failed the quality filter by not 
having a sequence tag length >0. MS/MS spectra were searched against UniProt human 
database. All spectra were allowed +/− 20 ppm mass tolerance for precursor and product 
ions, 30% minimum matched peak intensity, and “trypsin allow P” enzyme specificity with 
up to 2 missed cleavages. The fixed modifications were carbamidomethylation at cysteine, 
and TMT at N-termini and internal lysine residues. Variable modifications included oxidized 
methionine and N-terminal protein acetylation. Individual spectra were automatically 
designated as confidently assigned using the Spectrum Mill autovalidation module. 
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Specifically, a target-decoy based FDR scoring threshold criteria via a two-step auto 
threshold strategy at the spectral and protein levels was used. First, peptide mode was set to 
allow automatic variable range precursor mass filtering with score thresholds optimized to 
yield a spectral level FDR of <1.2%. A protein polishing autovalidation was applied to 
further filter the peptide spectrum matches using a target protein-level FDR threshold of 0. 
Following autovalidation, a protein-protein comparison table was generated, which 
contained experimental ratios. For all experiments, non-human contaminants and reversed 
hits were removed. Furthermore, data were filtered to only consider proteins with 2 or more 
unique peptides and was median normalized.
For statistical analysis, a moderated t-test was implemented in R-Shiny using the limma R 
library. Correction for multiple testing was performed using the Benjamini-Hochberg false 
discovery rate method.
Metabolic assays
Measurement of oxygen consumption and extracellular acidification rate: OCI-Ly and 
SU-DHL4 cells were counted and plated on a Seahorse 96-well plate at a density of 
1.25×105 or 5×105 cells, respectively in Seahorse XF DMEM media (Agilent). OCR and 
ECAR were simultaneously recorded using a Seahorse XF96 Analyzer (Agilent) for 12-38 
consecutive measurements. OCR is measured before and after the addition of inhibitors to 
assess mitochondrial function by deriving several parameters of mitochondrial respiration: 
(i) basal respiration, (ii) ATP-linked respiration and proton leak respiration (after 3 μM 
oligomycin [Sigma], a complex V inhibitor) and (iii) maximal respiration (after 1 μM 
carbonyl cyanide m-chlorophenyl hydrazine (CCCP) [Sigma], a protonophore). 
Mitochondrial respiration is finally inhibited by 1 μM antimycin A (Sigma), a complex III 
inhibitor.
To measure the effect of venetoclax on OCR/ECAR, cells were pre-treated for 1h with 10μM 
of zVAD-FMK (Abcam) or left untreated and OCR/ECAR were recorded for 4 
measurements before injection of venetoclax at a final concentration of 100 nM. DMSO 
injection was used as control.
Mitochondrial DNA copy number: Mitochondrial DNA copy number was determined 
using a multiplexed qPCR assay previously reported (Bao et al., 2016). QPCR quantification 
of relative abundance of mitochondrial (mtDNA) and nuclear (nucDNA) DNA was 
performed with the following primers and probes: ND2 forward (5’-
tgttggttatacccttcccgtacta-3’), ND2 reverse (5’-cctgcaaagatggtagagtagatga-3’), and probe (5’-
ccctggcccaaccc-3’, 6FAM on the 5’ end and MGBNFQ on the 3’ end) for detection of 
mtDNA; AluYb8 forward (5’-cttgcagtgagccgagatt-3’), AluYb8 reverse (5’-
gagacggagtctcgctctgtc-3’) and probe (5’-actgcagtccgcagtccggcct-3’, VIC on 5’, MGBNFQ 
on 3’) for detection of nucDNA. Cycling conditions for qPCR were the following: 95C for 
10 minutes followed by 40 cycles of 95C 15sec, 55C 15sec, 60C 1 min). Ten nanograms of 
genomic DNA extracted from OCI-LY1 S, OCI-LY1 R, SU-DHL4 S, SU-DHL4 R were 
used for this assay, in technical triplicates.
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Measurement of mitochondrial superoxide levels: To measure relative levels of 
mitochondrial superoxide, cells were stained with 5 μM MitoSOX Red (Invitrogen, cat# 
M36008) for 10 min at 37°C. Cells were then washed three times with the media. Using a 
flow cytometer (FACSymphony, BD), MitoSOX Red was excited at 488 nm and 
fluorescence emission at 610/20nm (BB630) was measured. Relative fluorescence intensity 
from biological triplicate of 10,000 cells were used as an indicator of mitochondrial 
superoxide levels.
Mitochondrial membrane potential: Cells were stained with 2.5 μM JC-1 (ThermoFisher 
Scientific, cat# T3168) for 30 min at 37 °C. Cells were then washed three times with the 
media and subjected to the flow cytometry (FACS-Canto) following manufacturer 
instruction. Briefly, JC-1 was excited at 488 nm and its emission at both 525 nm (FITC-A) 
and 585 nm (PE-A) were measured. By comparing the ratio of emission at 585nm/525nm, 
relative levels of mitochondrial membrane potential were determined from 10,000 cells in 
biological triplicate.
ATAC sequencing—ATAC-seq was performed on 50,000 cells as described (Buenrostro 
et al., 2013). Transposition reactions were performed for 1 hr at 37° C, followed by 
purification and sample barcoding by PCR. Samples were sequenced on an Illumina 
NextSeq 500, 35 base pair cycles in paired-end mode. ATAC-seq reads in fastq format were 
trimmed to remove adapter sequences using skewer v0.2.2.
Trimmed reads were aligned to hg19 using bowtie2 v2.3.3.1 (Langmead and Salzberg, 2012) 
with the following parameters:
'-D 20 -R 3 -N 1 -L 20 --local -i S,1,0.50 --rdg 5,1 --rfg 5,1 -X 2000'. Alignments were 
filtered using samtools v1.9 (Li and Durbin, 2009) to remove duplicate reads and retain only 
proper pairs with mapping quality greater than 30. Reads mapping to blacklisted regions 
were removed using samtools v1.9. Reads were converted to bed format and reads on the 
forward and reverse strands were shifted +4 and −5 bp respectively. MACS2 v2.1.1 (Zhang 
et al., 2008) was then used to call peaks and summits using the following parameters: '--
nomodel --extsize 200 --shift −100 --nolambda --keep-dup all −q 0.1'. IDR v2.0.4.2 was 
used to filter enriched regions at an IDR of less than 0.05 to produce high-confidence peak 
and summit sets. High-confidence summits were expanded to 500bp and a count matrix was 
generated with Rsubread v1.30.9 (Chen et al., 2016). This matrix was imported to R and 
chromVAR (Schep et al., 2017) was used in conjunction with motifs in the JASPAR2018 
(10.18129/B9.bioc.JASPAR2018) (Khan et al., 2018) and chromVARmotifs (https://
github.com/GreenleafLab/chromVARmotifs) R packages to generate motif-level measures of 
differential accessibility. Signal tracks were generated from bigwig files created from 
aligned bams using Deeptools v3.1.1 bamCoverage command (Ramírez et al., 2016) with 
the following parameters: "--Offset 1 -bs 50 --smoothLength 150 --maxFragmentLength 
2000 --scaleFactor SCALEFACTOR". Scaling factors for each sample were generated by 
quantifying total cutsites within each sample's IDR-filtered peaks and dividing by 1e6. 
Signal tracks for combined replicates were generated by first concatenating replicate fastqs, 
then applying the same processing steps described above.
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Immunohistochemistry and image acquisition—Immunohistochemical staining 
(IHC) for MCL1 (Clone 22, 1:100, Santa Cruz), Acetyl-CoA Carboxylase (Clone C83B10, 
1:50, Cell Signaling), Phospho-Acetyl-CoA Carboxylase (Clone D7D11, 1:50, Cell 
Signaling) or AMPKα (clone D5A2, 1:50, Cell Signaling) was performed using an 
automated staining system (BondRX, Leica Biosystems, Buffalo Grove, IL) according to the 
manufacturer’s protocol and as previously described (Roemer et al., 2016). Briefly, 4-μm 
thick formalin-fixed paraffin-embedded (FFPE) tissue sections were baked for 3h at 60 °C 
before loading onto the BOND RX. Slides were deparaffinized (BOND DeWax Solution, 
Leica Biosystems), rehydrated and antigen retrieval was performed onto the autostainer. 
Antigen retrieval was performed in BOND Epitope Retrieval Solution 1 (ER1, Leica 
Biosystems) at pH 6 for 30 min at 98 °C or Epitope Retrieval Solution 2 (ER2, Leica 
Biosystems) at pH 9 for 20 min at 98 °C as indicated above for each primary antibody. Next, 
slides were incubated with primary antibodies for 40 min. Subsequently, a secondary 
antibody of anti-rabbit Polymeric Horseradish Peroxidase (PolyHRP, BOND Polymer Refine 
Detection Kit, Leica Biosystems) was applied for 10 min. As a last step, slides were 
counterstained by hematoxylin for 5 minutes.
Image acquisition was performed using the Mantra imaging platform (Akoya PerkinElmer), 
as previously described (Carey et al., 2017). At least 5 or more representative regions of 
interest per section at 20x magnification were chosen by the pathologist within the tumor 
area. Areas without tumor or normal tissue were excluded from the analysis. Image Analysis 
was performed using the InForm 2.4 Image Analysis Software (PerkinElmer). All nucleated 
tumor cells within a field of view were identified via nuclear hematoxylin staining. Image 
analysis algorithms were trained by a pathologist to identify tumor cells that were positive 
for each of the targets above. A percentage of the total tumor cells identified that are positive 
for the stain of interest is given.
Quantitative PCR—The ID3 and PRKAR2B quantitative PCR assay was designed using a 
nested design, with outer primers for preamplification and inner primers for qPCR detection. 
ACTB and B2M were used as housekeeping genes. For cDNA reaction, 200 ng FFPE RNA 
or 100 ng fresh frozen RNA were dispensed to a PCR tube. Six qPCR replicates were 
performed per sample.
Quantification and Statistical Analysis
Data analyses were carried out using GraphPad Prism version 7 and R software. The data are 
summarized as mean ± s.e.m. or s.d. as indicated, and presented as individual values, scatter 
plots, heatmap or with column bar graphs. Data were analyzed using Student’s t-tests. One-
way ANOVA was used to compare three or more groups in time point analyses. Differences 
were considered significant when p < 0.05.
Synergy analysis for venetoclax drug combinations were performed using the Chou-Talalay 
method based on the median-effect principle (Chou, 2010). Combination index values and 
isobolograms were generated using CompuSyn. Excess over Bliss scores were calculated 
based on the Bliss Independence model of drug synergy (Bliss, 1939). Trajectory analyses 
for effect of venetoclax on metabolism were performed by looking at the least squares 
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regression of OCR/ECAR vs time for each cell line/treatment. Survival time data were 
calculated using the Kaplan-Meier method for and were compared by log-rank testing.
Data and Code Availability
The RNA seq and ATAC seq data discussed in this publication have been deposited in 
NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO 
Series accession number GSE 128563 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE128563).
The original mass spectra and sequence database used for searches may be downloaded from 
MassIVE (http://massive.ucsd.edu) using the identifier: MSV000083512. The dataset is 
directly accessible via ftp://massive.ucsd.edu/MSV000083512.
dbGaP accession number for the depositing of WES data for this study is phs001875.v1.p1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BCL-2 inhibition by venetoclax is approved for the treatment of myeloid and lymphoid 
leukemias. Here, we identify a mechanism by which lymphoid cancer cells can escape 
this compound by reprogramming cellular energy metabolism and overexpressing 
MCL-1. Our results provide important mechanistic insights as well as critical preclinical 
evidence supporting the use of metabolic modulators in combination with BCL-2 
inhibitors in patients with lymphoid malignancies.
Guièze et al. Page 31














• B-lymphoid cancer cells can escape to venetoclax by overexpressing MCL-1
• Modulation of AMPK/PKA axis and lymphoid transcription drive venetoclax 
resistance
• Venetoclax resistance involves changes in cellular energy metabolism such as 
OXPHOS
• Metabolic modulators can cooperate with venetoclax to overcome resistance
Guièze et al. show that resistance to the BCL-2 inhibitor venetoclax in chronic 
lymphocytic leukemia is associated with complex clonal shifts and identify, in addition to 
the known involvement by BCL-2 family members, regulators of lymphoid transcription 
and cellular energy metabolism as resistance drivers.
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Figure 1. CLL cells from patients developing resistance to venetoclax undergo clonal evolution 
and exhibit complex trajectories.
(A) Schema of the 6 studied patients (Pt) with timing and sites of pre- and post-treatment 
sample collections indicated.
(B) Comparison of the shifts in cancer cell fraction (CCF) in pre-treatment and relapse 
samples, demonstrating clonal evolution and diverse changes in subclonal composition 
across the 6 patients. Driver mutations associated with each clone are indicated. 
Superscripted numbers indicate distinct mutations of the same gene per patient. Del, 
deletion; amp, amplification.
(C) Comparison (modal CCF with 95% confidence interval) between pre-treatment and 
relapse samples for select drivers previously reported as recurrently observed in CLL. Mut, 
mutations.
See also Figure S1 and Tables S1-S4.
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Figure 2. BCL-2 family members, lymphoid transcription regulators and components of AMP-
dependent pathways are candidate drivers of venetoclax resistance.
(A) Experimental schema of the parallel knockout and overexpression screens using the 
BCL-2 driven OCI-Ly1 cell line (two biologically independent experiments per screen).
(B) sgRNAs frequencies at different timepoints during the screens (two independent 
experiments shown), black bars are mean +/− s.d., p value is from two-sided t-test.
(C) Scatter plots showing the average log2fold-change (LFC) for each gene in both 
duplicates of the loss-of-function screens (only genes with LFC > −1 are shown). Genes 
with a significant increase of sgRNAs representation (using the gene-ranking algorithm 
STARS, Broad Institute) are highlighted.
(D) ORF frequencies at different timepoints during the screens (two independent 
experiments shown), black bars are mean +/− s.d., p value is from two-sided t-test.
(E) Scatter plots showing the average log2fold-change (LFC) for each gene in both 
duplicates of the GOF screens (only genes with LFC > −1 are shown). Genes within the 
top-30 ORFs are highlighted.
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(F) Dose-response curves to venetoclax of 2 representative single-knockout OCI-Ly1 cells 
with related western-blots for quantification of the target protein. Data are mean +/− s.e.m.
(G) Cumulative growth over time of each of the genetically perturbed OCI-Ly1 cells.
See also Figure S2 and Tables S5 and S6.
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Figure 3. Expression changes related to acquisition of venetoclax resistance involves MCL-1 and 
cellular energy metabolism.
(A) Dose-response curve of the drug-resistant OCI-Ly1-R and the drug-sensitive OCI-Ly1-S 
cell lines. Data are mean +/− s.e.m.
(B) Scatter plot reporting log2fold-change (LFC) of expression levels of transcripts (X-axis) 
and proteins (Y-axis) levels between OCI-Ly1-S and OCI-Ly1-R cells. Red dots – events 
with adjusted p value < 0.05 at the protein level.
(C) Western-blot showing MCL-1, BCL-XL and BCL-2 protein levels in OCI-Ly1-S and 
OCI-Ly1-R cells.
(D) Dose-response curves of OCI-Ly1-S to venetoclax and varying doses of the MCL-1 
inhibitor S63845. Data are mean +/− s.e.m.
(E) Combination index according to the fraction affected (left) and normalized isobologram 
(right), Chou-Talalay method.
(F) Viability of the OCI-Ly1-R line 24 hours after exposure to venetoclax 100 nM, S63845 
50 nM and both drugs (and DMSO as control), data are mean +/− s.e.m. from three 
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biologically independent experiments; p value is from ANOVA test with adjustment for 
multiple comparisons.
See also Figure S3.
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Figure 4. Increased oxidative phosphorylation drives resistance to BCL-2 inhibition.
(A) Selected gene set enrichment analysis plots based on differential RNA expression 
between OCI-Ly1-S and OCI-Ly1-R.
(B) Oxygen consumption rate (OCR) as a function of time in the OCI-Ly1 and SU-DHL4 
lines, with exposure to inhibitors of the electron transport chain and oxidative 
phosphorylation (OXPHOS) to derive bioenergetics parameters of mitochondrial respiration.
(C) Quantification of the reactive oxygen species superoxide by flow cytometry in resistant 
vs parental B-cell lines.
(D) Ratio of mitochondrial DNA (mtDNA) over nuclear DNA (nucDNA) in resistant vs 
parental B-cell lines.
(E and F) Oxygen consumption rate (OCR) (E) and extracellular acidification rate (ECAR) 
(F) over time in the OCI-Ly1 and SU-DHL4 lines upon treatment by venetoclax, with or 
without prior zVAD treatment, or DMSO as control.
(G) Relative oxygen consumption rate (OCR) and over time in the control OCI-Ly1 and 
BAX/BAK1 double knockout OCI-Ly1 cell lines upon the treatment by venetoclax or 
DMSO as control.
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Data are mean +/− s.e.m. from three biologically independent experiments (panel C) and one 
representative experiment of three biological replicates (panel B, D, E, F and G), * denotes p 
< 0.0001. p value is from two-sided t-test.
See also Figure S3 and Table S7.
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Figure 5. Targeting AMPK or the mitochondrial electron transport chain modulates sensitivity 
to venetoclax.
(A) Dose-response curves of OCI-Ly1, SU-DHL4, SU-DHL6 and Toledo cell lines to 
increasing doses of venetoclax alone or in combination with the AMPK inhibitor 
dorsomorphin, the inhibitor of electron transport chain complex 3 antimycin and the F1Fo-
ATPase inhibitor oligomycin.
(B) Heatmap showing the Excess Over Bliss value related to the indicated combinations - 
venetoclax 5, 10 and 50 nM for OCI-Ly1 and 10, 50, 100, 5000, 1000, 5000 nM for SU-
DHL4, SU-DHL6 and Toledo, dorsomorphin 1 and 2 μM, oligomycin 10 and 100 nM, 
antimycin 10 and 100 nM.
(C) Heatmap of the mean viability from duplicate experiments of primary tumor cells 
collected from 10 CLL patients after exposure to various drugs combinations, as indicated 
(venetoclax 1 nM, dorsomorphin 2 μM, oligomycin 10 nM, antimycin 10 nM).
(D) Dose-response curves of indicated cell lines to increasing doses of venetoclax with and 
without exposure to the AMPK-activator A-769662.
(E) Viability of the resistant OCI-Ly1-R and SU-DHL4-R cell lines after exposure to 
venetoclax 500 nM with and without dorsomorphin 1 μM, antimycin 10 nM or oligomycin 
10 nM (DMSO as control).
For (A, C-E) viabilities were assessed at 24h of drugs exposure. For (A, D and E) the data 
shown represent mean +/− s.e.m. p value is calculated using a two-sided t-test.
(F) Tumor volume measurements of NSG OCI-Ly1 xenografts treated for 20 days, with 
vehicle control (black line), Oligomycin (200 mg/kg, i.p., pink line), Venetoclax (25 mg/kg, 
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p.o., dashed light blue line), or their combination (dark blue line). Data are mean +/− s.d. p 
values result from Repeated-Measures ANOVA test with Tukey’s correction.
See also Figure S4 and Table S1.
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Figure 6. A circuit of ID3 repression and PKA-AMPK deregulation is implicated in venetoclax 
resistance.
(A) Heatmap of differentially expressed transcripts between the OCI-Ly1-S and OCI-Ly1-R 
cells, and of knockout (KO) cell lines from the screen hits vs cell lines with KO using non-
targeting sgRNAs. Relevant genes affected in common with the OCI-Ly1-S and –R cells and 
in the ID3 KO line are indicated.
(B) Volcano plot of transcripts changes in ID3 KO OCI-Ly1 cells compared to non-targeting 
sgRNA transduced OCI-Ly1 cells.
(C) Volcano plot of enriched accessible transcription factor motifs comparing ID3 KO vs 
control.
(D) Western-blot quantification of ID2 and ID3 proteins in PRKAR2B and PRKAA2 
overexpressing OCI-Ly1 cell lines.
(E) Schema of the ID3 and PRKAR2B resistance circuit.
(F) Sensitivity of PRKAA2 and PRKAR2B overexpressing OCI-Ly1 cells to venetoclax 
when used in combination with dorsomorphin (2 μM) and oligomycin (1 μM), compared to 
DMSO control. Data are mean +/− s.e.m. from three biologically independent experiments, 
p value is from two-sided t-test.
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(G) Viability at 24 hours of single-cell clones from ID3 knockout OCI-Ly1 cells compared 
to non-targeting sgRNAs transduced OCI-Ly1 cells after exposure to dorsomorphin and 
oligomycin in addition to venetoclax. Data are mean +/− s.d. from three biologically 
independent experiments and p values are from ANOVA test.
See also Figure S5.
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Figure 7. Deregulated MCL-1 and AMPK signaling detected in CLL samples from patients 
developing resistance to venetoclax.
(A) Comparison of somatic copy number variations in the OCI-Ly1-S and OCI-Ly1-R cells. 
The red oval indicates amplification 1q as the main difference between the two lines. Red-
gain; blue - loss.
(B) Comparison (modal CCF with 95%CI) between pre-treatment and relapse leukemia 
samples from patients 1, 2 and 3 for amp(1q).
(C) Representation of the minimal gained region in the 1q locus across the OCI-Ly1-R cell 
line and relapsed samples from Patients 1, 2 and 3.
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(D) Immunohistochemical stains of patient samples before and after progression on 
venetoclax for MCL-1, AMPK, ACC, and p-ACC, with representative images from Patient 
C and 2 (left, the scale bar represents 20 μm in Patient 2 and 50 μm in Patient C), and 
quantification of % positively staining cells before (grey) and after (red) venetoclax 
treatment for Patients 2-6 (right). Data are mean +/− s.e.m. from replicates; p value is from 
Welch t-test.
(E) Progression-free survival according to MCL-1 expression (low, <10%; high, > or = 
10%). p value is from log rank test.
(F) Relative expression of ID3 by qPCR from patient sample RNA before (grey) and after 
(red) venetoclax treatment from Patients 2, 5, and 6; p value is from Welch t-test. The boxes 
extend from the 25th to 75th percentiles and the whiskers from min to max.
(G) Proposed model for venetoclax resistance in lymphoid malignancies.
See also Figure S6 and Tables S1-S4, and S8.
Guièze et al. Page 45

























Guièze et al. Page 46
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Bcl2 abcam Cat# ab59348, RRID:AB_2064155
Mcl-1 Santa Cruz Biotechnology
Cat# sc-12756, 
RRID:AB_627915
Bcl-xL Santa Cruz Biotechnology
Cat# sc-8392, 
RRID:AB_626739
Bim Cell Signaling Technology
Cat# 2819, 
RRID:AB_10692515
Bak Cell Signaling Technology
Cat# 3814, 
RRID:AB_2290287
Bax Cell Signaling Technology
Cat# 2772, 
RRID:AB_10695870
Pegasus Santa Cruz Biotechnology Cat# sc-517137
OTUD5 Cell Signaling Technology
Cat# 20087, 
RRID:AB_2798833
NOXA Santa Cruz Biotechnology
Cat# sc-56169, 
RRID:AB_784877
Id3 Cell Signaling Technology
Cat# 9837, 
RRID:AB_2732885
Id2 Cell Signaling Technology
Cat# 3431, 
RRID:AB_2122877
p300 Santa Cruz Biotechnology
Cat# sc-48343, 
RRID:AB_628075
UBR5 Cell Signaling Technology
Cat# 65344, 
RRID:AB_2799679
IkappaB-alpha Cell Signaling Technology
Cat# 9242, 
RRID:AB_331623
NF-1 Santa Cruz Biotechnology
Cat# sc-74444, 
RRID:AB_2153048
AMPK-alpha Cell Signaling Technology
Cat# 2532, 
RRID:AB_330331
AMPK-alpha Cell Signaling Technology Cat #5831
PKA beta Abcam Cat# ab94612, RRID:AB_10675826
GAPDH Cell Signaling Technology
Cat# 2118, 
RRID:AB_561053
Acetyl-CoA Carboxylase Cell Signaling Technology Cat# 3676
Phospho-Acetyl-CoA Carboxylase (Ser79) Cell Signaling Technology Cat# 11818
Bacterial and Virus Strains
NEB® 5-alpha Competent E. coli New England BioLabs C2987I
Biological Samples
Human CLL Primary Peripheral Blood Mononuclear Cells or Tissue DFCI, MDACC N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides and Recombinant Proteins
Venetoclax ABT-199 Selleck Chemicals S8048; CAS: 1257044-40-8
Venetoclax ABT-199 LC-Laboratories CAS#1257044-40-8
Dorsomorphin Sigma P5499; CAS: 866405-64-3
Oligomycin A Sigma 75351; CAS: 579-13-5
Antimycin A Sigma A8674; CAS: 1397-94-0
MCL-1 inhibitor S63845 Chemietek S-63845; CAS: CT-S63845




DNAeasy Blood and Tissue Kit Qiagen #69504
RNeasy FFPE Kit Qiagen #73504
Cell Titer-Glo Luminescent Cell Viability Assay Promega G7571
Pierce™ BCA Protein Assay Kit ThemoFisher #23225
QIAGEN Plasmid Maxi Kit Qiagen #12162
KAPA Biosciences 96-reaction kits Illumina KK8234
Quant-iT™ PicoGreen™ dsDNA Assay Kit ThemoFisher P11496
Nextera Rapid Capture Exome Kit Illumina #20020616
Quant-iT™ RiboGreen™ RNA Assay Kit ThemoFisher R11490
BOND Polymer Refine Detection Ki Leica Biosystems DS9800
Deposited Data
RNA seq and ATAC seq data This paper NCBI's Gene Expression Omnibus GSE 128563
Proteomics data This paper MassIVE database MSV000083512
WES data This paper dbGaP phs001875.v1.p1
Experimental Models: Cell Lines
OCI-Ly1 DSMZ ACC 722
SU-DHL-4 Letai lab, DFCI, Boston MA ATCC® CRL-2957™
SU-DHL-6 Letai lab, DFCI, Boston MA ATCC® CRL-2959™
Toledo ATCC ATCC® CRL-2631™
Mouse: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ The Jackson Laboratory JAX : 005557
Oligonucleotides
Primer: ID3 Single-cell Screening Forward: 5’-TGACAAGTTCCGGAGTGAGC-3’ This paper N/A
Primer: ID3 Single-cell Screening Reverse: 5’-CGGTATCAGCGCTTCCTCAT-3’ This paper N/A
ND2 forward: 5’-tgttggttatacccttcccgtacta-3’ Bao et al., 2016 N/A
ND2 reverse: 5’-cctgcaaagatggtagagtagatga-3’ Bao et al., 2016 N/A
mtDNA probe: 5’-ccctggcccaaccc-3’ Bao et al., 2016 N/A
AluYb8 forward: 5’-cttgcagtgagccgagatt-3’ Bao et al., 2016 N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
AluYb8 reverse: 5’-gagacggagtctcgctctgtc-3’ Bao et al., 2016 N/A
nucDNA probe: 5’-actgcagtccgcagtccggcct-3’ Bao et al., 2016 N/A
ID3 quantitative PCR Outer Forward: 5'-cgaCCACCTTCCCATCCAgaCA-3' This paper N/A
ID3 quantitative PCR Outer Reverse: 5'-tcgTCCTTTTGTCGTTGGAGATGACAA-3' This paper N/A
ID3 quantitative PCR inner Forward: 5'-acgCCAgaCAGCCGAGCTCA-3' This paper N/A
ID3 quantitative PCR inner Reverse: 5'-cgaGTTGGAGATGACAAGTTCCGGA-3' This paper N/A
PRKAR2B quantitative PCR Outer Forward: 5'-
cgaGAGAGCTTGCCCTGGTAACTAA-3' This paper N/A
PRKAR2B quantitative PCR Outer Reverse: 5'-
cgaCAAATGCTTGCACATCCATTgcTAA-3' This paper N/A
PRKAR2B quantitative PCR inner Forward: 5'-
cgtCTAACAAACCTCGAGCAGCTTCT-3' This paper N/A
PRKAR2B quantitative PCR inner Reverse: 5'-
cgaCATTgcTAAACATTTGACAGTCCCAA-3' This paper N/A
BAK1 gRNA1: 5'-AAGACCCTTACCAGAAGCAG-3' This paper N/A
BAK1 gRNA2: 5'-GGTAGACGTGTAGGGCCAGA-3' This paper N/A
BAX gRNA1: 5'-TCGGAAAAAGACCTCTCGGG-3' This paper N/A
BAX gRNA2: 5'-AGTAGAAAAGGGCGACAACC-3' This paper N/A
NFKBIA gRNA1: 5'-GGTTGGTGATCACAGCCAAG-3' This paper N/A
NFKBIA gRNA1: 5'-CTGGACGACCGCCACGACAG-3' This paper N/A
PMAIP1 gRNA1: 5'-TCGAGTGTGCTACTCAACTC-3' This paper N/A
PMAIP1 gRNA2: 5'-TTCTTGCGCGCCTTCTTCCC-3' This paper N/A
IKZF5 gRNA1: 5'-AGTTACTTCGATCACTGCAG-3' This paper N/A
IKZF5 gRNA2: 5'-ATCAGCTCTCGACTCTAGCA-3' This paper N/A
ID3 gRNA1: 5'-CTGGTACCCGGAGTCCCGAG-3' This paper N/A
ID3 gRNA2: 5'-TGGCCAGACTGCGTTCCGAC-3' This paper N/A
EP300 gRNA1: 5'-GTGGCACGAAGATATTACTC-3' This paper N/A
EP300 gRNA2: 5'-ATGGTGAACCATAAGGATTG-3' This paper N/A
NFIA gRNA1: 5'-TCCAGACTTTATCTGCCTGG-3' This paper N/A
NFIA gRNA2: 5'-CCCTGGATTAGAGCATTGTG-3' This paper N/A
OTUD5 gRNA1: 5'-CGGCGCAGGCTACAACAGTG-3' This paper N/A
OTUD5 gRNA2: 5'-GGTTGTGCGAAAGCATTGCA-3' This paper N/A
BCL2L11 gRNA1: 5'-TATGGATCGCCCAAGAGTTG-3' This paper N/A
BCL2L11 gRNA2: 5'-GTTCTGATGCAGCTTCCATG-3' This paper N/A
UBR5 gRNA1: 5'-TTGTTGTCTAAGAACGACGA-3' This paper N/A
UBR5 gRNA2: 5'-GCAACCAAGATAATGCTAGT-3' This paper N/A
TP53 gRNA1: 5'-GGATGATTTGATGCTGTCCC-3' This paper N/A
TP53 gRNA4: 5'-AGACGGAAACCGTAGCTGCC-3' This paper N/A
BAK1 gRNA1 target site F1 : 
TTGTGGAAAGGACGAAACACCGCCCATCTCTGCTTTTTCTCG This paper N/A
BAK1 gRNA1 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTTGATTGGCCAGCTTACTTCC This paper N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
BAK1 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGGGGCTCTCCACCAATGCTA This paper N/A
BAK1 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTGTACCACAAACTGGCCCAAC This paper N/A
BAX gRNA1 target site F1 : 
TTGTGGAAAGGACGAAACACCGCTTGGGGCTCAGTCTCCTTA This paper N/A
BAX gRNA1 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCCTGAGAGCAGGGATGTAGC This paper N/A
BAX gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGGCACTGGTTCTCCTCTCTCCT This paper N/A
BAX gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCACTTTACTTCACCCCTGCAC This paper N/A
NFKBIA gRNA1 target site F1 : 
TTGTGGAAAGGACGAAACACCGCCTGTCTAGGAGGAGCAGCA This paper N/A
NFKBIA gRNA1 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTGCATCCAATAGGCACTTTGC This paper N/A
NFKBIA gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGCCAGCCAGCGTTTATAGGG This paper N/A
NFKBIA gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCTTATGCAACCGGGGACTT This paper N/A
PMAIP1 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGCAGGTGCACATAAAGCCAAA This paper N/A
PMAIP1 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCAAGGGTCTTCCATTCTTGC This paper N/A
PMAIP1 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGCAGGACTGTTCGTGTTCAGC This paper N/A
PMAIP1 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTGCGAGGAGGAAAGAGAGGAG This paper N/A
IKZF5 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGTGCTTATGAGCGTCATCTGG This paper N/A
IKZF5 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTTCAGGGCAGGGAACTACATC This paper N/A
IKZF5 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGCCACGAAATCCCAAATATCC This paper N/A
IKZF5 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCTTGGCTGGCTGTTTCCTAT This paper N/A
ID3 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGAGCGGGACTTCTTTTGGTTT This paper N/A
ID3 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTGCCGTTTAAACCTCCCTCTC This paper N/A
ID3 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGAGCGGGACTTCTTTTGGTTT This paper N/A
ID3 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCTGGGTGTTCAGCCCTGT This paper N/A
EP300 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGTTGGTGACCCCTTTTTGAAG This paper N/A
EP300 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTTGAGCTGAGGCCTAGTTTTTC This paper N/A
EP300 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGCTGTCTTTGTGAACTTGGAAGTGA This paper N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
EP300 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCTCCTGTTTGGATCAACATGC This paper N/A
NFIA gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGCGACCCGAATATCGAGAGG This paper N/A
NFIA gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCTCAGGAAGAATCCGGCATA This paper N/A
NFIA gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGAGTCTGGAGGTTGGACCTTG This paper N/A
NFIA gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTAGGGTTTTCACGAGGCTTCT This paper N/A
OTUD5 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGGTGTGGGTGGTGCCGTAG This paper N/A
OTUD5 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCAGGGACTGGAATGACGACT This paper N/A
OTUD5 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGGGCATCTCTGACCCTAGCTG This paper N/A
OTUD5 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTTCCCATGGAATGTGTTGATG This paper N/A
BCL2L11 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGTGGACCACAATGTGATTTTTG This paper N/A
BCL2L11 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTTGCACAAGGGGAGTACAGAA This paper N/A
BCL2L11 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGGAGTGTGTGAGATGGGCTTG This paper N/A
BCL2L11 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTGTCTGTGCTCATAAAATTCCTTTGC This paper N/A
UBR5 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGCCAATTCATAAAGCAGTAGCTTAGG This paper N/A
UBR5 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCATCACAAATGCTCAAAGAGAG This paper N/A
UBR5 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGTCCTACCCCCTATGCCTTCT This paper N/A
UBR5 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTCTCTGACTGCACCACTGGAA This paper N/A
TP53 gRNA1 target site site F1 : 
TTGTGGAAAGGACGAAACACCGCTGGTAAGGACAAGGGTTGG This paper N/A
TP53 gRNA1 target site site R1 : 
TCTACTATTCTTTCCCCTGCACTGTGCCAAAGGGTGAAGAGGAAT This paper N/A
TP53 gRNA2 target site F1 : 
TTGTGGAAAGGACGAAACACCGGAAGACCCAGGTCCAGATGA This paper N/A
TP53 gRNA2 target site R1 : 
TCTACTATTCTTTCCCCTGCACTGTTCAAAAGCCAAGGAATACACG This paper N/A


























Guièze et al. Page 51
REAGENT or RESOURCE SOURCE IDENTIFIER






lentiCas9-Blast pXR101 Sanjana et al., 2014 Addgene Plasmid #52962
pXPR_011 Doench et al., 2014 Addgene Plasmid #59702
pMD2.G Trono's Lab Addgene Plasmid #12259
psPAX2 Trono's Lab Addgene Plasmid #12260
ORF PRKAR2B Broad Institute Clone ID TRCN0000480583
ORF PRKAA2 Broad Institute Clone ID TRCN0000492160
Human CRISPR Knockout Pooled Library (Brunello) Doench et al., 2016










RSEM-1.2.31 Li and Dewey et al., 2011
https://deweylab.github.io/
RSEM/





















Samtools v1.9 Li et al., 2009 http://samtools.sourceforge.net/
MACS2 v2.1.1 Zhang et al., 2008 https://github.com/taoliu/MACS/








JASPAR2018 Khan et al., 2018 http://jaspar.genereg.net/

















Guièze et al. Page 52
REAGENT or RESOURCE SOURCE IDENTIFIER
InForm 2.4 Image Analysis Software PerkinElmer https://www.perkinelmer.com
GraphPad Prism version 7 GraphPad https://www.graphpad.com/scientific-software/prism/
CompuSyn Chou et al., 2010 http://www.combosyn.com/












bwa version 0.5.9 Li and Durbin, 2010 http://bio-bwa.sourceforge.net/
ContEst Cibulskis et al., 2011 www.broadinstitute.org/cancer/cga
MuTect (version 1.1.6) Cibulskis et al., 2013 www.broadinstitute.org/cancer/cga
Strelka Saunders et al., 2012 www.broadinstitute.org/cancer/cga




deTiN algorithm Taylor-Weiner et al., 2018
www.broadinstitute.org/
cancer/cga
ReCapSeg Ramos et al., 2015 www.broadinstitute.org/cancer/cga
AllelicCapSeg Stachler et al., 2015 www.broadinstitute.org/cancer/cga
ABSOLUTE algorithm (v1.5) Carter et al., 2012 www.broadinstitute.org/cancer/cga
PhylogicNDT Leshchiner et al., 2018) N/A
Other
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